DNAPrint Genomics

DNAPrint Genomics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of DNAPrint Genomics (DNAG) as of Sep 25, 2026 is 49.99 %.

FCF Conversion

49.99 %

Last updated:

FCF Conversion Rate (FCF/EBITDA) of DNAPrint Genomics is 2026 49.99 % . FCF Conversion Rate (FCF/EBITDA) of DNAPrint Genomics was 2025 - . It decreases by % lower compared to the previous year.

The DNAPrint Genomics FCF Conversion history

The DNAPrint Genomics FCF Conversion history
YEARFCF ConversionYoY
49.99 %—
Access this data via the Eulerpool API

DNAPrint Genomics Stock analysis

What does DNAPrint Genomics do? DNAPrint Genomics Inc. was an American company specializing in researching genetic differences and their impact on health, diagnostics, and forensic applications. Founded in Sarasota, Florida in 1997, originally named Genaissance Pharmaceuticals, the company focused on medical research. In 2005, it changed its name to DNAPrint Genomics and shifted its focus to genetic testing development. The company's business model included developing and marketing molecular tests that can reveal an individual's genetic background, providing access to new markets and customers. DNAPrint Genomics offered various product lines for disease diagnosis, including tests for identifying and diagnosing specific diseases like breast cancer, colon cancer, and Alzheimer's. They also provided diagnostics for personalized medicine, matching medication to individuals' genetic predispositions. However, the company gained attention primarily for its forensic applications. They developed a system called DNAWitness, allowing comparison of unknown DNA samples with DNA databases to create offender profiles. The system was used by law enforcement agencies in the U.S. to aid crime investigation and was also involved in international police collaborations. DNAPrint Genomics pursued patents and partnerships with other companies to expand access to new technologies and developments, aiming to position itself in the international market. In 2008, the company announced its discontinuation due to economic reasons, facing complications in selling its DNAWitness system and encountering difficulties in selling its diagnostic tests. Despite having promising products, the company was unable to stabilize its market position and become profitable. DNAPrint Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DNAPrint Genomics stock

FCF Conversion Rate (FCF/EBITDA) of DNAPrint Genomics is 49.99 % in 2026.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) DNAPrint Genomics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s DNAPrint Genomics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — DNAPrint Genomics

All Key Metrics — DNAPrint Genomics